QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO. QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders. Founded in 1999, QPS Neuropharmacology has built a strong global reputation for high quality services that are deeply scientifically rooted and has an undisputed track-record of serving a loyal and broad customer base globally.
Read the full article: QPS Holdings, LLC Divests Its Neuropharmacology Business Unit //
Source: https://www.businesswire.com/news/home/20231130940694/en/QPS-Holdings-LLC-divests-its-Neuropharmacology-Business-Unit